Mihoko Sutoh Yoneyama

Papers

1

Total Citations

13

H-Index

1

About

Dr. Mihoko Sutoh Yoneyama is a pioneering urological researcher whose work centers on the development of liquid biopsy biomarkers for surgical and oncological applications. Her most impactful contribution is the investigation of total cell-free DNA (cfDNA) levels as a novel, non-invasive tool for evaluating surgical tissue damage—a critical gap in postoperative care where specific biomarkers have been lacking. In her highly cited 2021 study (13 citations), she demonstrated that perioperative cfDNA levels rise significantly following urological surgeries, offering a sensitive, real-time metric for assessing surgical trauma. This foundational work has opened new avenues for personalized recovery monitoring and early complication detection. Beyond this, Dr. Yoneyama’s broader research portfolio explores cfDNA dynamics in cancer and inflammation, positioning her at the forefront of translating circulating nucleic acids into clinical practice. Her studies are widely referenced by surgeons and molecular diagnosticians seeking objective damage markers, and her findings have been presented at major urology and oncology conferences. By bridging molecular biology and surgical care, Dr. Yoneyama is shaping a future where a simple blood test can guide postoperative management and improve patient outcomes.

Research Focus

Key Achievements

1
H-Index
1
Papers
13
Total Citations
13
Avg Citations/Paper
🏆 Most Cited Paper
Utility of total cell-free DNA levels for surgical damage evaluation in patients with urological surgeries
13 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 13

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago